Introduction {#s1}
============

Muscarinic receptors (MR) are typical members of G protein coupled receptors family (Kruse et al., [@B27]) and can be divided into 5 subtypes (M~1~--M~5~) (Eglen, [@B15]), which activate different G proteins (G~q~, G~i~). Odd-numbered subtypes activate G~q~, even-numbered activate G~i~ protein (Eglen, [@B15]; Kow and Nathanson, [@B26]; Reiner and Nathanson, [@B39]).

Respective MR subtypes have been assigned to different functions in CNS (Wess et al., [@B52]; Thomsen et al., [@B42]). Odd-numbered receptors are considered to be localized primarily post-synaptically, however, both M~2~MR and M~4~MR are localized both pre- and post-synaptically. As cholinergic autoreceptors, M~2~ and M~4~ provide feedback control of acetylcholine release (Zhang et al., [@B57]; Shin et al., [@B41]).

One of the means to determine MR density in different CNS areas is autoradiography. *In vitro* autoradiography has high sensitivity allowing to explore brain regions even with few MR. The use of very thin tissue sections *in vitro* autoradiography provides several advantages over the large tissue blocks used in binding studies in homogenates/membrane fractions. Brain sectioning allows analyzing MR density in virtually all brain areas of a single animal greatly reducing the number of experimental animals. Moreover, sectioning of a single brain generates sufficient number of tissue sections to explore the binding of multiple radioligands in a particular brain area of the same animal. This further reduces the number of experimental animals and allows comparing the effect of treatment on multiple targets (receptors, transporters) in a single animal (Farar and Myslivecek, [@B18]).

An important issue is the selectivity of radioligand used in experiments. A general problem in identification of MR subtypes present in specific regions of the central nervous system is the lack of highly subtype-selective muscarinic antagonists. The MR subtypes affinities for pirenzepine and AFDX-384, the most commonly used ones for discrimination of M~1~ and M~2~MR, respectively, are shown in Table [1](#T1){ref-type="table"}. It can be deduced from this table that both pirenzepine and AFDX-384 have not only high affinity for M~1~, and M~2~ MRs, respectively, but also for M~4~ MR subtype. In radioligand binding studies, it is therefore necessary to use a combination of various antagonists. However, for autoradiography detection this approach is not suitable because of evaluation limitations of such changed "binding." Thus, the present protocols for M~1~ and M~2~ MR subtypes identification should be considered as method for detection of M~1~ (or M~2~) and also yet unidentified portion of M~4~ MRs. Unfortunately, only few papers report these binding sites as M~2~/M~4~ MRs (e.g., Zavitsanou et al., [@B56]; Wang et al., [@B48]).

###### 

Muscarinic antagonist affinity constants (log affinity or pKi values) for mammalian muscarinic receptor subtypes.

                **Receptor subtype**                                    
  ------------- ---------------------- ---------- ---------- ---------- ----------
  Pirenzepine   7.8--8.5               6.3--6.7   6.7--7.1   7.1--8.1   6.2--7.1
  AF-DX 384     7.3--7.5               8.2--9.0   7.2--7.8   8.0-8.7    6.3
  PD 102807     5.3--5.5               5.7--5.9   6.2--6.7   7.3--7.4   5.2--5.5
  MT 7 toxin    9.8                    \<6        \<6        \<6        \<6
  MT 3 toxin    7.1                    \<6        \<6        8.7        \<6

*Data as referenced by Myslivecek et al. ([@B34])*.

The lack of MR subtype-selective ligands constitutes a significant obstacle in anatomical localization studies of MR, which are fundamental to our understanding of MR neuronal circuits. Three key strategies were developed to address regional distribution and relative abundance of particular MR subtype in the central nervous system.

First, *in situ* hybridization studies have identified neurons that synthetize MR (Buckley et al., [@B5]; Vilaró et al., [@B45]; Weiner et al., [@B50]). These and several other studies have shown that all five MR subtypes are expressed in the brain and mRNA for an individual MR subtype is distributed in a brain-region specific manner. However, while *in situ* hybridization studies provide valuable information about the sites of MR expression they do not address the real distribution of final proteins.

Second, MR subtype selective antibodies have been developed to map and quantify the distribution of individual MR by means of immunocytochemistry and immunoprecipitation (Levey et al., [@B30]; Yasuda et al., [@B55]). A body of reports have provided information about the distribution and quantities of individual MR. However, the reliability and selectivity of commonly used antibodies against MR have been questioned by their testing in specimens devoidof particular MR subtypes. This knockout-proof specific labeling has shown that the vast majority of tested antisera have identical labeling patterns in wild-type and knockout mice tissues (Jositsch et al., [@B25]).

Finally, anatomical localization and relative quantification of MR can be done by means *of in vitro* radioligand binding studies. This includes direct radioligand binding studies in tissue homogenates or plasma membrane preparation and indirect *in vitro* autoradiographic assays. *In vitro* autoradiography offers several advantages over direct binding studies. These includes tissue saving, high precision and reproducibility of results, high sensitivity and high degree of anatomical resolution. Moreover several ligands can be applied on consecutive sections derived from the same animal, further reducing numbers of experimental animals (Farar and Myslivecek, [@B18]).

Historically, tritiated pirenzepine was used as ligand that binds to MR with distinct binding in specific brain areas (Yamamura et al., [@B54]). Further, distinct distribution was found in the central nervous system. ^3^H-pirenzepine labels regions of the cerebral cortex, hippocampus, striatum and dorsal horn of the spinal cord, while sites in the cerebellum, nucleus tractus solitarius, facial nucleus and ventral horn of the spinal cord are labeled with ^3^H-QNB (non-specific muscarinic ligand) and not by ^3^H-pirenzepine (Wamsley et al., [@B47]). These observations indicated binding to different subtypes of MR. This was further expanded to definition of binding sites as M~1~ MR (Villiger and Faull, [@B46]). In the middle of eighties pirenzepine binding sites were considered as M~1~ MR (Buckley and Burnstock, [@B7]; Cortes and Palacios, [@B11]). On the other hand, ^3^H-AFDX-384 was considered from the beginning as a M~2~ MR specific ligand (Aubert et al., [@B1]) and some authors were aware of limited selectivity (e.g., Mulugeta et al., [@B33]). In many cases^3^H-AFDX-384 and ^3^H-pirenzepine are still considered as selective ligands (Tien et al., [@B44]; Wolff et al., [@B53]).

Here we performed series of *in vitro* autoradiographies with ^3^H-AFDX-384 (2 nM, concentration below K~D~ and the most commonly used one), and ^3^H-pirenzepine (5 nM, concentration below K~D~ and the most used one). We took advantage of knockout mice models in the standard autoradiography procedures to compare binding in WT, M~1~ KO, M~2~ KO and M~4~ KO mice. With this approach we addressed the selectivity of *in vitro* ^3^H-AFDX-384 autoradiography and provide a guide on the interpretation of results.

Moreover, we tried to block M~4~MR using three concentration of MT3 toxin isolated from Dendroaspis angusticeps venom (1, 10, and 100 nmol/l). Another method to disable the binding to M~4~MR was co-incubation with specific M~4~MR antagonist PD102807 (10, 100, and 1 μmol/l). With an aim to block M~1~MR we used MT7 toxin isolated from Dendroaspis angusticeps venom (1, 10, or 100 nmol/l) or pirenzepine (10 and 100 nmol/l).

In another of our experiment, using radiolabeled non-selective anatagonist, which binds all five MR subtypes (^3^H-QNB), we determined the contribution of M~1~, M~2~, and M~4~ MRs to the total expression of MRs in the mouse brain.

We can conclude that ^3^H-pirenzepine showed high selectivity toward M~1~MR. In contrast, ^3^H-AFDX-384 binding sites represent different populations of MR subtypes in a brain-region-specific manner. This finding has to be taken into account when interpreting the binding data not only in the autoradiographies but also when these antagonists (pirenzepine, AFDX-384, PD102807 or MT3 toxin) are used as a mean to detect M~1~MR, M~2~MR, or M~4~MR effects in functional studies. Experiments with ^3^H-QNB binding decrease in M~1~, $\text{M}_{2^{\cdot \cdot}}$, and M~4~ KO animals showed the highest proportion (usually above 50%) of M~1~MR in virtually all studied brain areas. M~2~MR take up to 20% in cortical areas and 34% in thalamus. M~4~MR were abundant (40% approximately) in thalamus, striatum and ventral striatum (NAc and OT), about 20% of M~4~MR can be found in cortical structures.

Methods {#s2}
=======

Drugs
-----

Atropine sulfate and pirenzepine dihydrochloride were purchased from Sigma-Aldrich (Sigma-Aldrich Co, St. Louis, MO, USA). PD102807 was purchased from Tocris Bioscience (Tocris Bioscience, Bristol, United Kingdom). MT3 toxin and MT7 toxin were purchased from Peptide Institute (Peptide Institute, Inc., Osaka, Japan). Pirenzepine \[N-methyl-^3^H\] (83.4 Ci/mmol), and AFDX-384 \[2,3-dipropylamino-3H\] (100.0 Ci/mmol) were from American Radiolabeled Chemicals (ARC, Inc.), Qinuclidinyl benzilate L-\[benzilic-4,4′-^3^H\] (50.5 Ci/mmol) was purchased from Perkin Elmer (Perkin Elmer Inc., USA).

Animals
-------

Mice were treated in accordance with the legislature of the Czech Republic and EU legislature \[European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (Council of Europe No 123, Strasbourg 1985)\], and the experimental protocol was approved by the Committee for the Protection of Experimental Animals of the 1st Medical Faculty, Charles University, Prague under N° MSMT-6316/2014-39.

Mice were maintained (3 per cage) under controlled environmental conditions (12 h/12 h light/dark cycle, 22±1°C, light on at 06:00 a.m.). Food and water were available *ad libitum*. Knockout mice and their WT counterparts of both genders (weighting 20--25 g, 11--13 weeks old), were used in the study. We studied fully backcrossed (at least 10 generations) muscarinic KO and WT littermates.

### M~1~ KO mice

Mice lacking M~1~ MR subtype were generated in the Wess laboratory (Bymaster et al., [@B8]) and then bred in our animal facility (Prague, Czech Republic). Their genetic background was C57Bl6/NTac. WT and KO genotypes were confirmed using polymerase chain reaction (PCR) analysis as previously described (Cea-del Rio et al., [@B10]).

### M~2~ KO mice

Mice lacking M~2~ MR subtype was generated in the Wess laboratory (Gomeza et al., [@B21]) and then bred in our animal facility (Prague, Czech Republic). The genetic background was maintained on C57Bl6/NTac mouse line. WT and KO genotypes were confirmed using PCR analysis as previously described (Cea-del Rio et al., [@B10]).

### M~4~ KO mice

Mice lacking M~4~ MR subtype were generated in Wess laboratory (Gomeza et al., [@B22]) and then bred in our animal facility (Prague, Czech Republic). Their genetic background was C57Bl6/NTac. WT and KO genotypes were confirmed using PCR analysis as previously described (Cea-del Rio et al., [@B10]).

Receptor autoradiography
------------------------

### Tissue preparation

For receptor determination, autoradiography was performed in several brain areas \[motor cortex (MOCx), somatosensory cortex (SSCx), visual cortex (VisCx), striatum (Caudatum-Putamen, CPu), nucleus accumbens (NAc), thalamus (TH), hippocampus (Hipp) and its specific areas CA1, CA3 and dentate gyrus (DG), olfactory tubercle (OT), pons (Pons), and medulla oblongata (MY)\] on sagittal brain sections of M~1~KO, M~2~KO, M~4~KO mice and their WT littermates. Brains were rapidly removed (4--6 brains per group), frozen on dry ice, and then stored at −80°C until cryostat sectioning. Sixteen-micrometer thick sagittal sections were cut on a cryostat at −20°C and thaw-mounted on Superfrost® Plus glass slides (Carl Roth GmbH & Co. KG, Karlsruhe, Germany) and stored in storage boxes at −80°C until use. For autoradiography experiments brain sections were allowed to thaw and dry for 30 min at 22°C.

### Autoradiography of muscarinic receptors on M~1~KO, M~2~KO, M~4~KO, and WT mice (^3^H-pirenzepine, ^3^H-AFDX-384, and ^3^H-QNB radioligand binding)

Brain sections were allowed to thaw and dry for 30 min at 22°C and density of receptors was determined as previously described (Farar et al., [@B17]; Farar and Myslivecek, [@B18]). Dry M~1~KO M~2~KO, M~4~KO, and WT sagittal brain sections were pre-incubated for 30 min in 50 mM potassium phosphate buffer (pH 7.4) at room temperature (RT). Following pre-incubation, sections were transferred into fresh 50 mM potassium phosphate buffer containing 2 nM ^3^H-AFDX-384, or 5 nM ^3^H-pirenzepine, or 2 nM ^3^H-QNB, and incubated for 60 min at RT. Non-specific binding was assessed on adjacent sections in the presence of 10 μM atropine sulfate. After incubation, sections were washed two times for 5 min each in ice-cold buffer and dipped for 2 s in ice-cold water to remove buffer salts. Wet sections were immediately dried by gentle stream of cold air. Dry sections were opposed to tritium sensitive Fuji BAS imaging plates (GE Healthcare Europe GmbH, Freiburg, Germany) in Kodak Biomax autoradiographic cassettes (Carestream Health, Inc., Rochester, NY).

### Autoradiography of M~2~ muscarinic receptors labeled with ^3^H-AFDX-384 and simultaneous blocking of M~4~ receptors with PD102807

The procedure was similar as described above. However, the sections were transferred into buffer containing 2 nM ^3^H-AFDX-384 together with 10; 100 or 1,000 nM PD102807 or without PD102807 but with addition of DMSO which serves as dissolving agent for PD102807 and incubated for 60 min at RT. The final concentration of DMSO in incubation buffer must be less than 1%, in our case it was 0.1%. The non-specific binding was assessed as described above. This specific experiment was conducted on M~2~ KO and M~4~ KO brain sections only. After incubation, sections were treated as stated above.

### Autoradiography of M~2~ muscarinic receptors labeled with ^3^H-AFDX-384 and simultaneous blocking of M~4~ receptors with MT3 toxin isolated from dendroaspis angusticeps venom

The procedure was similar as described above. However, the sections were transferred into buffer containing 2 nM ^3^H-AFDX-384 together with 1; 10 or 100 nM MT3 toxin or without MT3 toxin and incubated for 60 min at RT. Non-specific binding was assessed as described above. After incubation, sections were treated as described above.

### Autoradiography of M~2~ muscarinic receptors labeled with ^3^H-AFDX-384 and simultaneous blocking of M~1~ receptors with MT7 toxin isolated from dendroaspis angusticeps venom or with pirenzepine

The procedure was similar as described above. However, the sections were transferred into buffer containing 2 nM ^3^H-AFDX-384 together with 10 or 100 nM pirenzepine or without pirenzepine (serves as control) and incubated for 60 min at RT. Blocking of M~1~ MR with MT7 toxin was conducted as following: the brain sections were at first pre-incubated with different concentrations of MT7 toxin (1; 10 or 100 nM) for 45 min. After pre-incubation with MT7, ^3^H-AFDX-384 with final concentration 2 nM was added into the buffer containing MT7 toxin and incubated for another 45 min. Non-specific binding as mentioned earlier. After incubation, sections were processed as described above.

### Quantification of receptor density

To assure linearity of the signal, autoradiographic standards (American Radiolabeled Chemicals, Inc., St. Louis, MO, USA) were exposed along with the samples to the screens. Imaging plates were processed in Fuji Bioimaging Analyzer BAS-5000 (FUJIFILM corporation, Tokio, Japan) and digitized images analyzed with MCID analysis software (InterFocus GmbH, Mering, Germany). Measurements were taken and averaged from three sections for each animal and brain region.

Statistical analysis
--------------------

Statistical significance between groups was determined using 1-way ANOVA with Sidak *post-hoc* analysis. Student\'s *t*-test was used for comparison between two groups (typically WT vs. KO only).

Results {#s3}
=======

The selectivity of ^3^H-pirenzepine toward M~1~MR
-------------------------------------------------

Autoradiography with ^3^H-pirenzepine showed high selectivity of this ligand toward M~1~MR (see Figure [1](#F1){ref-type="fig"}). In many brain areas, except in CPu and OT the binding in M~1~ KO animals decreased by 90--99% (see Table [2](#T2){ref-type="table"}). Especially, in hippocampal areas (dorsal hippocampus, CA1, CA3 area, and DG) ^3^H-pirenzepine binding sites were almost completely abolished. Please note very low binding in TH. The selectivity of pirenzepine was confirmed in M~2~ KO animals (see Table [3](#T3){ref-type="table"}) where no significant difference was shown in M~2~ KO animals when compared to WT animals. Similar results were obtained when using M~4~ KO animals (see Table [4](#T4){ref-type="table"}). However, in some brain areas, we found small, but significant decrease in ^3^H-pirenzepine binding in M~4~ KO animals (MOCx, SSCx, VisCx, CPu; 7, 13, 9, and 11%, respectively).

![Changes in ^3^H-pirenzepine specific binding in M~1~KO mice (**top**) and ^3^H-AFDX binding in M~2~KO (**middle**) and M~4~KO mice (**bottom**) when compared to WT animals. Non-specific binding was determined in the presence of 10 μM atropine sulfate. Ordinate: brain areas \[motor cortex (MOCx), somatosensory cortex (SSCx), visual cortex (VisCx), striatum (Caudatum-Putamen, CPu), nucleus accumbens (NAc), thalamus (TH), hippocampus (Hipp) and its specific areas CA1, CA3, and dentate gyrus (DG), olfactory tubercle (OT)\], abscissa: relative density \[nCi/mg\]. WT, wild type; KO, knockout mice. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001.](fphar-09-00124-g0001){#F1}

###### 

Percentage difference in ^3^H-pirenzepine binding in M~1~KO, and in ^3^H-AFDX-384 to M~2~KO, and M~4~KO animals to WT animals.

  **M**~**1**~**KO (**^**3**^**H-pirenzepine)**   **M**~**2**~**KO (**^**3**^**H-AFDX-384)**   **M**~**4**~**KO (**^**3**^**H-AFDX-384)**                                 
  ----------------------------------------------- -------------------------------------------- -------------------------------------------- --------- ---------- -------- ----------
  MOCx                                            −95.85                                       \<0.0001                                     −54.38    \<0.0001   −37.82   \<0.0001
  SSCx                                            −94.14                                       \<0.0001                                     −51.08    \<0.0001   −40.04   \<0.0001
  VisCx                                           −94.35                                       \<0.0001                                     −47.19    \<0.0001   −43.23   \<0.0001
  Hipp                                            −98.49                                       \<0.0001                                     −28.32    \<0.0001   −24.03   =0.00100
  TH                                              −76.68                                       =0.0096                                      −100.00   \<0.0001   −39.31   =0.0001
  CPu                                             −86.49                                       \<0.0001                                     −15.19    =0.0290    −77.46   \<0.0001
  NAc                                             −90.71                                       \<0.0001                                     −23.99    =0.0036    −73.78   \<0.0001
  OT                                              −89.23                                       \<0.0001                                     −8.48     NS         −74.62   \<0.0001
  CA1                                             −99.48                                       \<0.0001                                     −23.19    =0.0007    −22.41   0.0022
  CA3                                             −99.10                                       \<0.0001                                     −50.10    \<0.0001   −19.64   =0.0064
  DG                                              −99.41                                       \<0.0001                                     −19.86    =0.0028    −17.62   =0.0077

*Statistical significance determined using unpaired Student t-test. For abbreviations see text*.

###### 

Binding and percentage difference in ^3^H-pirenzepine binding in M~2~KO animals and WT animals.

  **Brain area**   **Relative density \[nCi/mg\]**   **Difference from WT (%)**   **Significance (*p*)**   
  ---------------- --------------------------------- ---------------------------- ------------------------ ----
  MOCx             37.27 ± 1.11                      37.50 ± 0.67                 1.46                     NS
  SSCx             37.31 ± 1.15                      36.20 ± 0.73                 1.01                     NS
  VisCx            38.81 ± 1.54                      39.41 ± 0.89                 0.82                     NS
  Hipp             57.32 ± 1.66                      58.46 ± 0.90                 1.32                     NS
  CPu              47.87 ± 1.75                      48.52 ± 0.91                 2.01                     NS
  NAc              56.57 ± 2.30                      54.51 ± 1.70                 1.54                     NS
  OT               47.13 ± 2.87                      50.25 ± 1.02                 2.60                     NS
  CA1              65.45 ± 1.71                      66.03 ± 0.84                 1.26                     NS
  CA3              43.46 ± 0.95                      43.66 ± 0.38                 1.32                     NS
  DG               58.85 ± 2.00                      58.95 ± 0.89                 1.42                     NS

*Statistical significance determined using unpaired Student t-test. For abbreviations see text*.

###### 

Binding and percentage difference in ^3^H-pirenzepine binding in M~4~KO animals and WT animals.

  **Brain area**   **Relative density \[nCi/mg\]**   **Difference from WT (%)**   **Significance**   
  ---------------- --------------------------------- ---------------------------- ------------------ ---------
  MOCx             36.86 ± 0.78                      34.39 ± 0.67                 −6.71              =0.0369
  SSCx             35.98 ± 1.13                      31.26 ± 0.73                 −13.11             =0.0057
  VisCx            37.32 ± 1.16                      34.02 ± 0.89                 −8.83              =0.0473
  Hipp             54.94 ± 1.45                      54.99 ± 0.90                 0.10               NS
  CPu              47.85 ± 1.65                      42.46 ± 0.91                 −11.27             =0.0170
  NAc              55.20 ± 1.65                      52.81 ± 1.70                 −4.33              NS
  OT               46.58 ± 2.85                      42.10 ± 1.02                 −9.61              NS
  CA1              62.96 ± 1.31                      62.78 ± 0.84                 −0.28              NS
  CA3              44.48 ± 1.35                      44.00 ± 0.38                 −1.07              NS
  DG               55.28 ± 1.73                      55.97 ± 0.89                 1.25               NS

*Statistical significance determined using unpaired Student t-test. For abbreviations see text*.

The selectivity of ^3^H-AFDX-384 toward M~2~MR
----------------------------------------------

In contrast to the above mentioned experiment, ^3^H-AFDX-384 did not show selectivity toward M~2~MR. If ^3^H-AFDX-384 was highly selective toward M~2~MR, the binding of ^3^H-AFDX-384 would be barely visible in M~2~ KO mice, as they do not express M~2~MR. As it can be deduced from Figure [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}, the binding reduction in many brain areas varied between 20 and 50%, with exception of pons, medulla oblongata and TH, where uniform population of M~2~MR was found. Olfactory tubercle is the only area, in which the binding of ^3^H-AFDX-384 was completely preserved.

The selectivity of ^3^H-AFDX-384 toward M~4~MR
----------------------------------------------

Similar to the experiment in M~2~ KO mice, the binding in M~4~ KO mice showed only limited selectivity of ^3^H-AFDX-384 toward this MR subtype. However, ^3^H-AFDX-384 had similar selectivity to M~4~MR and M~2~MR (see Figure [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}). A decrease in ^3^H-AFDX-384 binding depends on the brain area analyzed. This experiment also verified that pons and medulla oblongata express only M~2~MR which can be deduced from the unchanged binding in M~4~ KO mice. However, thalamus was not confirmed as an area with only M~2~MR. Representative autoradiograms for M~1~, M~2~ and M~4~ WT and KO mice are shown in Figure [2](#F2){ref-type="fig"}.

![Representative autoradiograms in WT and KO mice: ^3^H-pirenzepine binding in M~1~ WT and KO mice (**top**), ^3^H-AFDX 384 binding in M~2~ WT and KO mice (**middle**), and ^3^H-AFDX 384 binding in M~4~ WT and KO mice (**bottom**).](fphar-09-00124-g0002){#F2}

Binding of ^3^H-AFDX-384 in the presence of M~4~MR antagonist PD102807
----------------------------------------------------------------------

The effort to block M~4~MR using antagonist PD102807 was unsuccessful as demonstrated in M~2~ KO mice and M~4~ KO mice. When the slices were incubated with 1 μmol/l of PD102807, we have recorded 100% inhibition of residual binding in M~2~ KO mice (see Table [5](#T5){ref-type="table"}). However, PD102807 also dose-dependently reduced ^3^H-AFDX-384 binding in M~4~ KO mice, suggesting limited selectivity toward M~4~MR.

###### 

Binding and percentage difference in ^3^H-AFDX 384 binding with PD102807 in M~2~KO, and M~4~KO animals vs. control (no PD102807).

  **Brain area**                **M~2~KO \[nCi/mg\] x ± SEM**   **M~2~KO control vs. M~2~KO PD**   ***P*-value**   **M~4~KO \[nCi/mg\] x ± SEM**   **M~4~KO control vs. M~4~KO PD**   ***P*-value**
  ---------------- ------------ ------------------------------- ---------------------------------- --------------- ------------------------------- ---------------------------------- ---------------
  MOCx             Control      13.76 ± 1.388                                                                      16.78 ± 1.060                                                      
                   10 nM PD     5.668 ± 0.053                   −58.81                             \<0.001         12.67 ± 1.482                   −24.49                             =0.021
                   100 nM PD    5.365 ± 0.051                   −61.01                             \<0.001         12.35 ± 0.458                   −26.40                             = 0.029
                   1000 nM PD   0 ± 0.000                       −100.00                            \<0.001         8.157 ± 1.140                   −51.39                             \<0.001
  SSCx             Control      17.25 ± 1.977                                                                      18.42 ± 1.460                                                      
                   10 nM PD     6.654 ± 0.882                   −61.43                             \<0.001         13.79 ± 0.923                   −25.14                             =0.017
                   100 nM PD    5.325 ± 0.057                   −69.13                             \<0.001         11.11 ± 1.216                   −39.69                             =0.002
                   1000 nM PD   0 ± 0.000                       −100.00                            \<0.001         8.563 ± 1.040                   −53.51                             \<0.001
  VisCx            Control      16.39 ± 2.554                                                                      16.66 ± 1.067                                                      
                   10 nM PD     6.858 ± 0.530                   −58.16                             \<0.001         13.22 ± 1.444                   −20.65                             =0.091
                   100 nM PD    5.769 ± 0.078                   −64.80                             \<0.001         9.092 ± 1.588                   −45.43                             =0.003
                   1000 nM PD   0 ± 0.000                       −100.00                            \<0.001         6.69 ± 1.117                    −59.84                             \<0.001
  Hipp             Control      14.82 ± 1.028                                                                      12.76 ± 0.464                                                      
                   10 nM PD     7.857 ± 0.726                   −46.98                             \<0.001         8.926 ± 0.976                   −30.05                             =0.005
                   100 nM PD    5.972 ± 0.406                   −59.70                             \<0.001         6.632 ± 0.670                   −48.03                             \<0.001
                   1000 nM PD   0 ± 0.000                       −100.00                            \<0.001         6.233 ± 0.966                   −51.15                             \<0.001
  CPu              Control      48.23 ± 3.175                                                                      10.69 ± 1.012                                                      
                   10 nM PD     31.33 ± 0.238                   −35.04                             \<0.001         6.896 ± 1.074                   −35.49                             =0.006
                   100 nM PD    20.44 ± 1.202                   −57.62                             \<0.001         6.123 ± 0.551                   −42.72                             =0.003
                   1000 nM PD   0 ± 0.000                       −100.00                            \<0.001         5.598 ± 0.238                   −47.63                             =0.002
  NAc              Control      43.92 ± 4.107                                                                      11.52 ± 1.251                                                      
                   10 nM PD     31.42 ± 2.005                   −28.46                             \<0.001         8.234 ± 1.101                   −28.52                             =0.029
                   100 nM PD    18.1 ± 0.674                    −58.79                             \<0.001         6.641 ± 0.634                   −42.35                             =0.006
                   1000 nM PD   0.168 ± 0.058                   −99.62                             =0.002          6.478 ± 0.588                   −43.77                             =0.008
  OT               Control      44.55 ± 4.201                                                                      7.048 ± 0.399                                                      
                   10 nM PD     21.73 ± 1.338                   −51.22                             \<0.001         5.452 ± 0.212                   −22.64                             \<0.001
                   100 nM PD    8.894 ± 0.253                   −80.04                             \<0.001         0.425 ± 0.145                   −93.97                             \<0.001
                   1000 nM PD   0 ± 0.000                       −100.00                            \<0.001         0 ± 0.000                       −100.00                            \<0.001

*Statistical significance determined using one-way ANOVA with post-hoc Sidak analysis. PD, PD102807. For other abbreviations see text*.

Binding of ^3^H-AFDX-384 in the presence of M~4~MR specific toxin MT3
---------------------------------------------------------------------

Similar to PD102807, MT3 toxin was unable to block M~4~MR. This can be seen in competitions binding experiment with increasing concentration of MT3 toxin (Table [6](#T6){ref-type="table"}). MT3 toxin was unable to completely block residual ^3^H-AFDX-384 binding in M~2~ KO mice. Moreover, MT3 also dose-dependently reduced ^3^H-AFDX-384 binding in M~4~ KO mice.

###### 

Binding and percentage difference in ^3^H-AFDX 384 binding with MT3 toxin in M~2~KO, and M~4~KO animals vs. control (no MT3 toxin).

  **Brain area**                **M~2~KO \[nCi/mg\] x ± SEM**   **M~2~KO control vs. M~2~KO MT3**   ***P*-value**   **M~4~KO \[nCi/mg\] x ± SEM**   **M~4~KO control vs. M~4~KO MT3**   ***P*-value**
  ---------------- ------------ ------------------------------- ----------------------------------- --------------- ------------------------------- ----------------------------------- ---------------
  MOCx             Control      11.01 ± 0.234                                                                       15.61 ± 0.821                                                       
                   1 nM MT3     9.32 ± 0.422                    −15.35                              \<0.001         14.81 ± 0.427                   −5.12                               NS
                   10 nM MT3    4.468 ± 0.125                   −59.42                              \<0.001         13.86 ± 1.874                   −11.21                              NS
                   100 nM MT3   2.115 ± 0.081                   −80.79                              \<0.001         10.57 ± 0.470                   −32.29                              =0.018
  SSCx             Control      13.42 ± 0.468                                                                       15.15 ± 2.011                                                       
                   1 nM MT3     10.97 ± 0.870                   −18.26                              =0.009          15.95 ± 0.509                   5.28                                NS
                   10 nM MT3    5.173 ± 0.479                   −61.45                              \<0.001         13.17 ± 1.678                   −13.07                              NS
                   100 nM MT3   2.393 ± 0.145                   −82.17                              \<0.001         11.08 ± 0.514                   −26.86                              NS
  VisCx            Control      13.59 ± 0.822                                                                       14.79 ± 2.159                                                       
                   1 nM MT3     10.52 ± 0.617                   −22.59                              =0.005          14.97 ± 1.241                   1.22                                NS
                   10 nM MT3    4.949 ± 0.648                   −63.58                              \<0.001         13.08 ± 2.405                   −11.56                              NS
                   100 nM MT3   2.177 ± 0.361                   −83.98                              \<0.001         11.69 ± 1.124                   −20.96                              NS
  Hipp             Control      11.37 ± 0.445                                                                       13.37 ± 1.158                                                       
                   1 nM MT3     9.061 ± 0.217                   −20.31                              \<0.001         12.29 ± 0.925                   −8.08                               NS
                   10 nM MT3    5.851 ± 0.436                   −48.54                              \<0.001         9.094 ± 0.503                   −31.98                              =0.006
                   100 nM MT3   2.824 ± 0.227                   −75.16                              \<0.001         7.16 ± 0.489                    −46.45                              \<0.001
  CPu              Control      31.59 ± 1.035                                                                       9.659 ± 0.128                                                       
                   1 nM MT3     26.94 ± 1.756                   −14.72                              =0.01           8.931 ± 0.192                   −7.54                               NS
                   10 nM MT3    8.836 ± 0.641                   −72.03                              \<0.001         7.81 ± 1.325                    −19.14                              NS
                   100 nM MT3   3.03 ± 0.275                    −90.41                              \<0.001         5.041 ± 0.129                   −47.81                              =0.001
  NAc              Control      30.7 ± 0.446                                                                        12.19 ± 0.071                                                       
                   1 nM MT3     24.85 ± 1.185                   −16.49                              =0.001          10.42 ± 0.722                   −14.52                              NS
                   10 nM MT3    9.884 ± 1.270                   −61.22                              \<0.001         8.9 ± 1.771                     −26.99                              NS
                   100 nM MT3   3.879 ± 0.791                   −78.13                              \<0.001         5.827 ± 0.489                   −52.20                              =0.002
  OT               Control      29.65 ± 1.640                                                                       9.134 ± 0.302                                                       
                   1 nM MT3     21.68 ± 2.434                   −18.30                              =0.003          8.757 ± 0.234                   −4.13                               NS
                   10 nM MT3    6.838 ± 0.700                   −67.82                              \<0.001         7.729 ± 1.025                   −15.38                              NS
                   100 nM MT3   2.501 ± 0.067                   −82.73                              \<0.001         5.306 ± 0.152                   −41.91                              =0.001

*Statistical significance determined using one-way ANOVA with post-hoc Sidak analysis. MT3, MT3 toxin. For other abbreviations see text*.

Binding of ^3^H-AFDX-384 in the presence of pirenzepine and M~1~MR specific toxin MT7 in WT and M~4~ KO mice
------------------------------------------------------------------------------------------------------------

Incubation with pirenzepine (Table [7](#T7){ref-type="table"}) showed dose-dependent reduction of ^3^H-AFDX-384 binding both in WT and M~4~ KO mice. Irreversible, and very specific toxin MT7 also dose-dependently reduced ^3^H-AFDX-384 binding in both WT and M~4~ KO mice (see Table [8](#T8){ref-type="table"}).

###### 

Binding and percentage difference in ^3^H-AFDX 384 binding with pirenzepine in M~4~WT and M~4~KO animals vs. control (no pirenzepine).

  **Brain area**                **M~4~WT (nCi/mg)**   **M~4~KO (nCi/mg)**   **WT vs. KO (%)**   ***P*-value**   **M~4~WT control vs. M~4~ WT PIR**   **P-value**   **M~4~ KO control vs. M~4~ KO PIR**   ***P*-value**
  ---------------- ------------ --------------------- --------------------- ------------------- --------------- ------------------------------------ ------------- ------------------------------------- ---------------
  MOCx             Control      20.310 ± 0.389        13.96 ± 0.285         −31.27              =0.0002                                                                                                  
                   10 nM PIR    17.89 ± 1.835         10.2 ± 0.490          −42.98              =0.0155         −11.92                               NS            −26.93                                \<0.001
                   100 nM PIR   11.56 ± 2.226         6.387 ± 0.081         −44.75              NS              −43.08                               =0.01         −54.25                                \<0.001
  SSCx             Control      23.210 ± 1.275        14.61 ± 0.487         −37.05              =0.0041                                                                                                  
                   10 nM PIR    21.22 ± 3.075         11.21 ± 0.690         −47.17              =0.0336         −8.57                                NS            −23.27                                \<0.001
                   100 nM PIR   12.93 ± 2.132         6.525 ± 0.134         −49.54              =0.0401         −44.29                               =0.022        −55.34                                \<0.001
  VisCx            Control      22.480 ± 0.936        13.61 ± 0.503         −39.46              =0.0011                                                                                                  
                   10 nM PIR    20.35 ± 2.271         9.741 ± 0.598         −52.13              =0.0107         −9.48                                NS            −28.43                                \<0.001
                   100 nM PIR   11.27 ± 1.824         6.166 ± 0.202         −45.29              =0.0496         −49.87                               =0.003        −54.70                                \<0.001
  Hipp             Control      16.830 ± 0.75         12.87 ± 0.366         −23.53              =0.009                                                                                                   
                   10 nM PIR    13.57 ± 1.581         7.637 ± 0.492         −43.72              =0.0231         −19.37                               NS            −40.66                                \<0.001
                   100 nM PIR   7.402 ± 1.23          3.507 ± 0.069         −52.62              =0.0341         −56.02                               \<0.001       −72.75                                \<0.001
  CA1              Control      20.640 ± 0.495        15.66 ± 0.603         −24.13              =0.0031                                                                                                  
                   10 nM PIR    16.35 ± 1.756         9.162 ± 0.698         −43.96              =0.019          −20.78                               NS            −41.49                                \<0.001
                   100 nM PIR   8.91 ± 1.556          4.185 ± 0.016         −53.03              =0.0384         −56.83                               \<0.001       −73.28                                \<0.001
  CA3              Control      15.830 ± 0.59         13.71 ± 0.433         −13.39              =0.0437                                                                                                  
                   10 nM PIR    13.45 ± 1.65          8.743 ± 0.728         −35.00              NS              −15.03                               NS            −36.23                                \<0.001
                   100 nM PIR   8.3 ± 1.437           4.491 ± 0.035         −45.89              NS              −47.57                               =0.0006       −67.24                                \<0.001
  DG               Control      14.120 ± 0.934        10.96 ± 0.217         −22.38              =0.0303                                                                                                  
                   10 nM PIR    10.76 ± 1.625         6.024 ± 0.504         −44.01              =0.0497         −23.80                               NS            −45.04                                \<0.001
                   100 nM PIR   5.185 ± 0.856         2.174 ± 0.089         −58.07              =0.0249         −63.28                               \<0.001       −80.16                                \<0.001
  CPu              Control      33.670 ± 1.684        8.953 ± 0.301         −73.41              =0.0001                                                                                                  
                   10 nM PIR    30.9 ± 4.385          6.062 ± 0.271         −80.38              =0.0048         −8.23                                NS            −32.29                                \<0.001
                   100 nM PIR   16.68 ± 3.283         2.733 ± 0.251         −83.62              =0.0133         −50.46                               =0.011        −69.47                                \<0.001
  NAc              Control      33.230 ± 1.947        10.25 ± 0.418         −69.15              =0.0003                                                                                                  
                   10 nM PIR    29.9 ± 5.43           6.884 ± 0.032         −76.98              =0.0133         −10.02                               NS            −32.84                                \<0.001
                   100 nM PIR   16.24 ± 3.941         3.311 ± 0.152         −79.61              =0.0306         −51.13                               =0.031        −67.70                                \<0.001
  TH               Control      11.460 ± 0.571        7.224 ± 0.179         −36.96              =0.0021                                                                                                  
                   10 nM PIR    10.22 ± 2.177         6.239 ± 0.468         −38.95              NS              −10.82                               NS            −13.64                                =0.04
                   100 nM PIR   7.757 ± 1.203         3.615 ± 0.043         −53.40              =0.0263         −32.31                               NS            −49.96                                \<0.001
  MY               Control      13.670 ± 0.617        11.08 ± 1.107         −18.95              NS                                                                                                       
                   10 nM PIR    13.58 ± 1.278         11.03 ± 1.926         −18.78              NS              −0.66                                NS            −0.45                                 NS
                   100 nM PIR   10.48 ± 2.456         5.237 ± 0.819         −50.03              NS              −23.34                               NS            −52.73                                \<0.001
  Pons             Control      15.110 ± 0.079        13.51 ± 1.279         −10.59              NS                                                                                                       
                   10 nM PIR    14.34 ± 1.558         10.55 ± 1.058         −26.43              NS              −5.10                                NS            −21.91                                NS
                   100 nM PIR   11.15 ± 1.414         6.253 ± 0.806         −43.92              =0.0396         −26.21                               NS            −53.72                                =0.02
  OT               Control      28.830 ± 2.339        8.797 ± 0.335         −69.49              =0.0011                                                                                                  
                   10 nM PIR    25.86 ± 4.201         5.554 ± 0.225         −78.52              =0.0085         −10.30                               NS            −36.86                                \<0.001
                   100 nM PIR   14.81 ± 3.031         3.647 ± 0.087         −75.37              =0.0212         −48.63                               =0.029        −58.54                                \<0.001

*Statistical significance determined using one-way ANOVA with post-hoc Sidak analysis or Student unpaired t-test (WT. vs. KO). PIR. pirenzepine. For other abbreviations see text*.

###### 

Binding and percentage difference in ^3^H-AFDX 384 binding with MT7 toxin in M~4~WT, and M~4~KO animals vs. control (no MT7 toxin).

  **Brain area**                **M~4~WT (nCi/mg)**   **M~4~KO (nCi/mg)**   **WT vs. KO (%)**   ***P*-value**   **M~4~WT control vs. M~4~WT MT7**   ***P*-value**   **M~4~ KO control vs. M~4~KO MT7**   ***P*-value**
  ---------------- ------------ --------------------- --------------------- ------------------- --------------- ----------------------------------- --------------- ------------------------------------ ---------------
  MOCx             Control      24.600 ± 1.55         14.36 ± 1.078         −41.63              =0.0056                                                                                                  
                   1 nM MT7     20.01 ± 0.683         13.13 ± 0.721         −34.38              =0.0023         −18.66                              =0.008          −8.57                                NS
                   10 nM MT7    18.59 ± 1.079         10.47 ± 0.347         −43.68              =0.002          −24.43                              =0.003          −27.09                               =0.004
                   100 nM MT7   12.72 ± 0.478         8.829 ± 0.429         −30.59              =0.0037         −48.29                              \<0.001         −38.52                               \<0.001
  SSCx             Control      28.820 ± 3.316        15.46 ± 0.310         −46.36              =0.0116                                                                                                  
                   1 nM MT7     22.66 ± 1.221         13.65 ± 0.992         −39.76              =0.0046         −21.37                              =0.032          −11.71                               NS
                   10 nM MT7    20.55 ± 0.484         11.52 ± 0.492         −43.94              =0.0002         −28.70                              =0.014          −25.49                               =0.002
                   100 nM MT7   13.76 ± 0.393         9.774 ± 0.660         −28.97              =0.0066         −52.26                              \<0.001         −36.78                               \<0.001
  VisCx            Control      26.070 ± 2.892        14.66 ± 0.404         −43.77              =0.0175                                                                                                  
                   1 nM MT7     19.86 ± 1.131         12.59 ± 0.943         −36.61              =0.0078         −23.82                              =0.039          −14.12                               =0.022
                   10 nM MT7    19.77 ± 1.097         10.43 ± 0.286         −47.24              =0.0012         −24.17                              =0.021          −28.85                               \<0.001
                   100 nM MT7   13.23 ± 0.339         8.466 ± 0.326         −36.01              =0.0005         −49.25                              \<0.001         −42.25                               \<0.001
  Hipp             Control      21.780 ± 1.544        13.92 ± 0.594         −36.09              =0.009                                                                                                   
                   1 nM MT7     14.54 ± 1.974         10.24 ± 1.214         −29.57              NS              −33.24                              =0.002          −26.44                               =0.002
                   10 nM MT7    11.77 ± 0.091         6.862 ± 0.019         −41.70              \<0.0001        −45.96                              \<0.001         −50.70                               \<0.001
                   100 nM MT7   7.866 ± 0.216         5.084 ± 0.171         −35.37              =0.0005         −63.88                              \<0.001         −63.48                               \<0.001
  CA1              Control      25.060 ± 1.829        17.13 ± 0.417         −31.64              =0.0134                                                                                                  
                   1 nM MT7     17.28 ± 2.268         13.04 ± 1.280         −24.54              NS              −31.05                              =0.003          −23.88                               =0.001
                   10 nM MT7    14.11 ± 0.277         8.038 ± 0.066         −43.03              \<0.0001        −43.70                              \<0.001         −53.08                               \<0.001
                   100 nM MT7   9.703 ± 0.329         6.093 ± 0.264         −37.20              =0.001          −61.28                              \<0.001         −64.43                               \<0.001
  CA3              Control      21.060 ± 1.332        14.75 ± 0.766         −29.96              =0.0148                                                                                                  
                   1 nM MT7     15.02 ± 1.5           11.47 ± 0.885         −23.64              NS              −28.68                              =0.001          −22.24                               =0.003
                   10 nM MT7    12.56 ± 0.164         8.534 ± 0.265         −32.05              =0.0002         −40.36                              \<0.001         −42.14                               \<0.001
                   100 nM MT7   9.442 ± 0.15          6.995 ± 0.259         −25.92              =0.0012         −55.17                              \<0.001         −52.58                               \<0.001
  DG               Control      19.310 ± 1.564        11.71 ± 0.831         −39.36              =0.0127                                                                                                  
                   1 nM MT7     12.16 ± 2.077         7.982 ± 1.237         −34.36              NS              −37.03                              =0.002          −31.84                               =0.004
                   10 nM MT7    8.006 ± 0.369         4.122 ± 0.126         −48.51              =0.0006         −58.54                              \<0.001         −64.80                               \<0.001
                   100 nM MT7   5.174 ± 0.146         2.891 ± 0.228         −44.12              =0.0011         −73.21                              \<0.001         −75.31                               \<0.001
  CPu              Control      43.410 ± 2.14         9.207 ± 0.708         −78.79              =0.0001                                                                                                  
                   1 nM MT7     36.24 ± 2.251         7.941 ± 0.775         −78.09              =0.0003         −16.52                              =0.013          −13.75                               NS
                   10 nM MT7    33.01 ± 0.556         5.169 ± 0.109         −84.34              \<0.0001        −23.96                              =0.002          −43.86                               \<0.001
                   100 nM MT7   20.24 ± 1.477         4.422 ± 0.498         −78.15              =0.0005         −53.37                              \<0.001         −51.97                               \<0.001
  NAc              Control      42.830 ± 2.79         11.28 ± 0.934         −73.66              =0.0004                                                                                                  
                   1 nM MT7     37.61 ± 2.622         9.917 ± 1.342         −73.63              =0.0007         −12.19                              NS              −12.08                               NS
                   10 nM MT7    28.85 ± 1.266         5.076 ± 0.165         −82.41              \<0.0001        −32.64                              NS              −55.00                               \<0.001
                   100 nM MT7   18.52 ± 1.236         4.323 ± 0.410         −76.66              =0.0004         −56.76                              NS              −61.68                               \<0.001
  TH               Control      14.750 ± 1.189        7.696 ± 0.574         −47.82              =0.0059                                                                                                  
                   1 nM MT7     12.03 ± 0.894         7.895 ± 0.271         −34.37              =0.0115         −18.44                              NS              2.59                                 NS
                   10 nM MT7    12.55 ± 0.189         7.525 ± 0.181         −40.04              \<0.0001        −14.92                              NS              −2.22                                NS
                   100 nM MT7   8.785 ± 0.235         6.125 ± 0.236         −30.28              =0.0013         −40.44                              \<0.001         −20.41                               =0.024
  MY               Control      16.190 ± 1.489        15.27 ± 1.625         −5.68               NS                                                                                                       
                   1 nM MT7     15.98 ± 0.165         15.87 ± 1.658         −0.69               NS              −1.30                               NS              3.93                                 NS
                   10 nM MT7    15.91 ± 0.526         13.79 ± 1.579         −13.32              NS              −1.73                               NS              −9.69                                NS
                   100 nM MT7   12.67 ± 0.393         10.61 ± 1.615         −16.26              NS              −21.74                              =0.03           −30.52                               NS
  Pons             Control      15.030 ± 2.633        12.79 ± 2.748         −14.90              NS                                                                                                       
                   1 nM MT7     14.3 ± 1.235          12.49 ± 2.741         −12.66              NS              −4.86                               NS              −2.35                                NS
                   10 nM MT7    14.52 ± 1.612         11.97 ± 2.159         −17.56              NS              −3.39                               NS              −6.41                                NS
                   100 nM MT7   11.45 ± 1.458         9.407 ± 2.037         −17.84              =0.0226         −23.82                              NS              −26.45                               NS
  OT               Control      36.610 ± 3.097        9.624 ± 0.857         −73.71              =0.0011                                                                                                  
                   1 nM MT7     31.46 ± 2.283         6.451 ± 0.725         −79.49              =0.0005         −14.07                              NS              −32.97                               =0.003
                   10 nM MT7    26.16 ± 1.063         4.969 ± 0.219         −81.01              \<0.0001        −28.54                              =0.006          −48.37                               \<0.001
                   100 nM MT7   16.16 ± 0.13          4.094 ± 0.323         −74.67              \<0.0001        −55.86                              \<0.001         −57.46                               \<0.001

*Statistical significance determined using one-way ANOVA with post-hoc Sidak analysis or Student unpaired t-test (WT vs. KO). MT7, MT7 toxin. For other abbreviations see text*.

Binding of ^3^H-QNB in WT and M~1~ KO, M~2~ KO, and M~4~ KO mice
----------------------------------------------------------------

### M~1~ KO mice

Binding decrease in M~1~ KO mice (Figure [3](#F3){ref-type="fig"}, top) showed high densities of M~1~ MR in almost all brain areas. In cortical structures, there was approximately 60% of M~1~ MR (64, 58, and 61% in MoCx, SSCx, and VisCx, respectively). The highest density of M~1~ MR was found in hippocampus (91%) and in hippocampal regions (CA1: 89%, CA3 88%, dentate gyrus 98%, respectively). In striatum, there was 37%. Similar density of M~1~ MR was found ventral striatum, i.e., in NAc (46%) and OT (48%).

![Changes in ^3^H-QNB specific binding in M~1~KO mice (**top**), M~2~KO mice (**middle**), and M~4~KO mice (**bottom**) when compared to WT animals. Non-specific binding was determined in the presence of 10 μM atropine sulfate. Ordinate: brain areas \[motor cortex (MOCx), somatosensory cortex (SSCx), visual cortex (VisCx), medulla oblongate (MY), pons Varoli (pons), striatum (Caudatum-Putamen, CPu), nucleus accumbens (NAc), thalamus (TH), hippocampus (Hipp) and its specific areas CA1, CA3 and dentate gyrus (DG), olfactory tubercle (OT)\], abscissa: relative density \[nCi/mg\]. WT, wild type; KO, knockout mice. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001.](fphar-09-00124-g0003){#F3}

### M~2~ KO mice

Binding decrease in M~2~ KO mice (Figure [3](#F3){ref-type="fig"}, middle) showed relatively low density of M~2~ MRs in MoCx, SSCx, and VisCx (20, 22, 21%, respectively). In pons and medulla oblongata, there was 100% decrease suggesting pure M~2~ MR population in these regions.

### M~4~ KO mice

The decrease in binding in M~4~ KO mice (Figure [3](#F3){ref-type="fig"}, bottom) revealed 21, 26, and 27% of M~4~ MRs in MoCx, SSCx, and VisCx, respectively. The population of M~4~ MRs is represented by 43% of total number of MRs in the thalamus. However, the muscarinic population in thalamus is low. The highest proportion of M~4~ MRs was found in CPu, NAc, OT, where it represents 46, 38, and 49%, respectively.

Discussion {#s4}
==========

Here we used knockout proof concept to ascertain the selectivity of well-established and commonly used autoradiography protocols for labeling of putative M~2~ and M~1~MR. Putative M~2~ and M~1~MR were labeled with ^3^H-AFDX-384 and ^3^H-pirenzepine, respectively. We compared the pattern and relative density of ^3^H-AFDX-384 and ^3^H-pirenzepine specific binding sites in WT with M~1~, M~2~, and M~4~ KO mice.

Our results demonstrate that ^3^H-pirenzepine labels predominantly, albeit not exclusively, M~1~MR. Thus, according to our results, ^3^H-pirenzepine can be used as M~1~MR selective ligand in brain cortex (MOCx, SSCx, VisCx) and hippocampus, in which more than 94% of ^3^H-pirenzepine binding sites are attributable to M~1~MR. In the striatum and olfactory tubercle 10--13% of ^3^H-pirenzepine specific binding sites correspond to another MR subtype. Apart from these limitations, ^3^H-pirenzepine can be considered (in concentration 5 nmol/l and in the protocol described in Methods section) as M~1~MR specific ligand.

To test whether ^3^H-pirenzepine binds also to M~4~MR, we performed also ^3^H-pirenzepine autoradiography in M~4~ KO mice, (see Table [1](#T1){ref-type="table"} for affinities). We assumed, that in case that ^3^H-pirenzepine binds M~4~MR, there should be decrease in ^3^H-pirenzepine binding in M~4~ KO mice. Indeed, ^3^H-pirenzepine binding in M~4~KO mice is decreased in cortical areas and in caudate putamen. This result can be explained, however by two ways. Firstly, ^3^H-pirenzepine binds to M~4~MR. Secondly, M~1~MR are decreased in M~4~ KO mice. M~4~MR are enriched in the striatum and expressed at modest level in cortex (Gomeza et al., [@B22]). Therefore, the decrease of ^3^H-pirenzepine binding due to the lack of M~4~MR should be mostly seen in striatum and not in the cortex. We showed that there is decrease in ^3^H-pirenzepine binding by 11% in striatum of M~4~ KO mice and that the residual binding of ^3^H-pirenzepine in M~1~ KO mice is 10--13%. This suggest that indeed, in striatum ^3^H-pirenzepine binds also to M~4~MR. In contrast, there was more than 95% reduction of ^3^H-pirenzepine binding in cortex of M~1~ KO mice. The density of M~4~MR in the cortex is approximately three-fold lower than in the striatum, but decrease in ^3^H-pirenzepine binding in cortex of M~4~ KO mice was similar to that in striatum. Taken together, decrease in ^3^H-pirenzepine binding in the cortex of M~4~ KO mice suggests rather alteration in the density of M~1~ MR than binding to M~4~MR. Once again and taking above mentioned results into account, we can consider ^3^H-pirenzepine as M~1~MR highly specific ligand.

In contrast, ^3^H-AFDX-384 has poor selectivity toward M~2~MR and labels mixed population of MR in a brain area dependent manner. Autoradiography in M~2~ and M~4~KO mice showed that ^3^H-AFDX-384 binds to multiple MR populations and that this population differs between brain areas. Moreover, ^3^H-AFDX-384 binds to M~4~MR subtype in similar way as to M~2~MR subtype what is in contrast to opinion that ^3^H-AFDX-384 is M~2~MR preferential ligand. Our working hypothesis was that in case of ^3^H-AFDX-384 high selectivity toward M~2~MR, gene deletion of M~2~MR resulting in absence of M~2~MR protein in M~2~KO mice should result in complete loss of ^3^H-AFDX-384-specific binding. Even though ^3^H-AFDX-384 specific binding was reduced in M~2~KO mice throughout the brain, the reduction was far less than expected. Surprisingly ^3^H-AFDX-384 specific binding was also reduced in M~4~KO mice. In brain regions rich in M~4~MR, such as striatum the ^3^H-AFDX-384 specific binding was reduced more than 70%. This suggest that^3^H-AFDX-384 binds to M~4~MR subtype as well. Even though affinity of AFDX-384 is high (see Table [1](#T1){ref-type="table"}), the extent of ^3^H-AFDX-384 binding to M~4~MR in vitro autoradiography is surprising. In order to increase the selectivity of ^3^H-AFDX-384 toward M~2~MR, we tried to block ^3^H-AFDX-384 binding to M~4~MR by addition of antagonist PD102807 (with pKi higher by two orders of magnitude for M~4~MR than for other MR subtypes: 7.3--7.4 vs. 5.2--6.7, see Table [1](#T1){ref-type="table"}). Assuming the high selectivity of PD102807 for M~4~MR and binding of ^3^H-AFDX-384 also to M~4~MR, PD102807 should markedly reduce the residual ^3^H-AFDX-384 binding in M~2~KO mice. Indeed, addition of PD102807 into incubation medium dose-dependently reduced the residual ^3^H-AFDX-384 specific binding in M~2~KO mice, suggesting effective blocking of putative M~4~MR. At the highest concentration (1,000 nmol/l), there was no residual binding of ^3^H-AFDX-384 in M~2~KO mice. To test the potential binding capacity of PD102807 to other MR subtypes we performed similar experiment in M~4~KO mice. In case that PD102807 is selective M~4~MR ligand, adding PD102807 to the incubation medium should not interfere with ^3^H-AFDX-384 with binding capacity in M~4~KO mice, since there are no M~4~MR. However, PD102807 also dose-dependently reduced ^3^H-AFDX-384 specific binding in M~4~KO mice with no M~4~MR, indicating that under our experimental conditions PD102807 has poor selectivity toward M~4~MR. Assuming that ^3^H-AFDX-384 predominantly labels M~2~MR and M~4~MR and no other MR subtype our results suggest, that PD102807 binds to both M~4~MR and M~2~MR. We can therefore conclude that co-incubation with PD102807 is not a suitable protocol for M~4~MR binding elimination and M~2~MR specific binding autoradiography. Thus, we explored another specific binding antagonist---MT3 toxin from Dendroaspis angusticeps venom---with effort to eliminate binding to M~4~MR. This toxin is believed to block binding to M~4~MR with great order of magnitude difference to other MR subtypes (pKi = 8.7 (M~4~MR) vs. \< 6 in M~2~, M~3~, M~5~MR and 7.1 in M1MR, see Table [1](#T1){ref-type="table"}). Similarly to PD102807, MT3 toxin was unable to effectively block ^3^H-AFDX-384 binding to M~4~MR. There remained ^3^H-AFDX-384 binding capacity in M~2~ KO mice in the highest (100 nmol/l) MT3 toxin concentration which should be able to block all M~4~MR. Moreover, similarly to PD102807, MT3 not only dose-dependently decreased residual binding of ^3^H-AFDX-384 in M~2~ KO mice, but also in M~4~ KO mice. This suggest that MT3 toxin does not distinguish between M~4~ and M~2~MR, at least under our experimental conditions. Finally, we tested the hypothesis that ^3^H-AFDX-384 binds also to M~1~MR. We tested our hypotheses in M~4~ KO animals using two approaches: binding in the presence of pirenzepine (see Table [1](#T1){ref-type="table"} for affinities) and irreversible, and very specific toxin MT7 (with pKi = 9.8 to M~1~MR and pKi \<6 to other muscarinic subtypes). We choose M~4~ KO mice in order to exclude possible binding of pirenzepine toward M~4~MR in striatum as discussed above. Even at 10 nM concentration, pirenzepine significantly reduced ^3^H-AFDX-384 specific binding in M~4~ KO mice, suggesting that ^3^H-AFDX-384 binds to a certain extent also M~1~MR. Moreover, irreversible, and very specific toxin MT7 showed dose-dependent reduction of ^3^H-AFDX-384 specific binding in M~4~ KO mice further supporting binding of ^3^H-AFDX-384 to M~1~MR. It is therefore possible to conclude that ^3^H-AFDX-384 is not suitable ligand for M~2~MR. Moreover, we were not successful in designing any protocol to block M~4~ or M~1~MR and increase the selectivity of ^3^H-AFDX-384 autoradiography of M~2~MR.

All five MR subtypes are highly expressed in the brain (Levey et al., [@B30]; Wess et al., [@B51]; Oki et al., [@B36]). The M~1~ and M~4~ MRs represent the most abundant subtypes with the highest expression in the cortex, hippocampus and striatum that can be well illustrated using ^3^H-QNB autoradiography in our M~1~ KO and M~4~ KO mice.

*In vitro* receptor autoradiography has been used for decades for mapping anatomical distribution and quantification of broad range of receptors (Manuel et al., [@B31]; Farar and Myslivecek, [@B18]). The standard autoradiography is based on equilibrium binding of radioactively labeled antagonist. The key aspect of autoradiography is thus the selectivity of radioligand toward its target. MR subtypes show often overlapping pattern of expression and most MR ligands have poor selectivity, making the discrimination of individual subtypes difficult. While there are several ligands available, which specifically label MR, they do not distinguish individual MR subtypes. *In vitro* heterologous expression systems have helped to describe the affinity of a broad range of antagonists toward each of the five MR (Buckley et al., [@B6]; Dörje et al., [@B14]; Dong et al., [@B13]). These studies have identified so-called preferential MR ligands such as AFDX-384 and pirenzepine, which are commonly used to target putative M~2~ and M~1~MR, respectively. AFDX-384 has the highest affinity toward M~2~MR, but also similar affinity toward M~4~MR (Dörje et al., [@B14]).

We have proofed here that autoradiography protocol for ^3^H-pirenzepine is suitable for M~1~MR detection (with limitations in CPu, NAc and OT) where pirenzepine binds also by approximately 10% to another MR subtype, likely M~4~MR). Thus, this ligand can be used as M~1~MR specific as before (e.g., Wamsley et al., [@B47]; McCabe et al., [@B32]; Farar and Myslivecek, [@B18]).

On the other hand, ^3^H-AFDX-384 is not suitable to detect M~2~MR as believed previously (Entzeroth and Mayer, [@B16]; Wolff et al., [@B53]; Grailhe et al., [@B23]). However, there are some studies that previously correctly defined ^3^H-AFDX-384 as M~2~ partially selective (Mulugeta et al., [@B33]) or as M~2~/M~4~ ligand (Nieves-Martinez et al., [@B35]).

The fact that ^3^H-AFDX-384 is not selective toward M~2~MR was predictable in the light of AFDX-384 affinity to MR subtypes (see Table [1](#T1){ref-type="table"}). However, almost identical binding to M~2~MR and M~4~MR is a new finding. We also tried to find specific protocol for M~2~MR specific binding using different antagonists (PD102807, MT3 toxin, pirenzepine, and MT7 toxin). None of these antagonists were able to completely block other receptors. And thus it is necessary to conclude that there is no way to make the binding more specific to M~2~MR.

Another aspect of our data is demonstration of M~1~MR, M~2~MR, and M~4~MR distribution. It can be deduced from Figure [1](#F1){ref-type="fig"} that M~1~MR are not as hugely present in the cortical structures as in some hippocampal areas (dorsal hippocampus, CA1 area, and dentate gyrus). Very low M~1~MR density is in the thalamus. Comparing binding in M~2~WT and M~2~KO mice we can conclude that there is relatively high density of M~2~MR in cortical structures, medulla oblongata, pons and thalamus. In contrast, hippocampus and striatum does not have high amount of M~2~MR. Striatum is, however, rich in M~4~MR similarly to nucleus accumbens and olfactory tubercles. Also, the density of M~4~MR in the cortex is relatively high. However, one should take into account that these data represent relative proportions of respective MR subtypes, since the binding was determined in radioligand concentrations around K~D~ and the receptors were not saturated. ^3^H-pirenzepine has pK~D~ around 7.9 (Watson et al., [@B49]), ^3^H-AFDX 384 has KD between 3 and 4 nmol.l^−1^ (Castoldi et al., [@B9]) what is comparable to ^3^H-pirenzepine. In order to verify the proportion of respective MR subtypes we have used specific MR knockouts (M~1~, M~2~, and M~4~ KOs) and measured a decrease in non-specific radioligand (^3^H-QNB) binding. This radioligand has much higher affinity to MR and pK~D~ ranging between 10.6 and 10.8 (Peralta et al., [@B37]). These experiments showed the highest proportion (usually above 50%) of M~1~MR in virtualy all studied brain areas. M~2~MR take up to 20% in cortical areas and 34% in thalamus. M~4~MR were abundant (40% approximately) in thalamus, striatum and ventral striatum (NAc and OT), about 20% of M~4~MR can be found in cortical structures. This is in general agreement with previously published data (Levey et al., [@B30]; Wess et al., [@B51]; Oki et al., [@B36]), although we have obtained slightly different pattern of MR subtypes distribution what can be caused by the use of different radioligand. Some discrepancies between results could be attributed to the fact that not all antibodies are selective (Pradidarcheep and Michel, [@B38]). As referenced by Manuel et al. ([@B31]) relatively good correlation exists between the radioligand detected receptor number and the immunolabeled receptor protein for M~1~ subtype.

Our results concerning the MR distribution are generally in in agreement with previous study (Oki et al., [@B36]) which employed different muscarinic knockouts but used non-specific radioligand (^3^H-NMS). However, in this study less brain areas were investigated and different method (direct radioligand binding) used. We sldo found similar pattern of MR subtype distribution as investigated using antibodies and electron microscopy (Hersch et al., [@B24]), immunoprecipitation (Levey et al., [@B30]; Tice et al., [@B43]) and radioligand binding (Flynn and Mash, [@B20]). Another study (Ferrari-Dileo et al., [@B19]) that used selective labeling found similar pattern of M~4~MR distribution as here. All five MR subtypes are highly expressed in the brain (Levey, [@B29]; Oki et al., [@B36]). The M~1~ and M~4~ MR represent the most abundant subtypes with the highest expression in the cortex, hippocampus and striatum that can be well illustrated using ^3^H-QNB autoradiography in our M~1~ KO and M~4~ KO mice. Previous research has shown that MRs, mostly M~1~ and M~4~ MRs, might be an interesting pharmacological target for the treatment of neurodegenerative and neuropsychiatric diseases such as Alzheimer\'s disease, Parkinson\'s disease, schizophrenia, depression and also drug abuse (Bodick et al., [@B2]; Scarr et al., [@B40]; Brady et al., [@B4]; Langmead et al., [@B28]; Bradley et al., [@B3]; Dall et al., [@B12]). Therefore, *in vitro* radioligand binding studies, direct and indirect, represent an important pharmacological tool to precisely characterize the involvement of specific MR subtypes in such a disease as well as to study the binding properties, affinity and efficacy of new chemical compounds with the potential to become a selective drug toward the receptor.

Conclusion {#s5}
==========

We can therefore conclude that ^3^H-pirenzepine showed high selectivity toward M~1~MR and can be used with minor limitations as M~1~MR specific ligand. In contrast, ^3^H-AFDX-384 binding sites represent different populations of MR subtypes which is brain-region-specific. This finding has to be taken into account when interpreting the binding data. Our experiments with ^3^H-QNB binding decrease in M~1~, $\text{M}_{2^{\cdot \cdot}}$, and M~4~ KO animals showed the highest proportion of M~1~MR in virtualy all studied brain areas. M~2~MR were expressed in cortical areas and in thalamus. M~4~MR were abundant in thalamus, striatum and ventral striatum (NAc and OT as well as in cortical structures.
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